CCR5 and metabolic dysfunction-associated steatotic liver disease: These results led us to hypothesize that blockade of CCR5 signaling on g-MDSCs may reduce lipogenic and, to some extent, pro-inflammatory gene expression in hepatocytes under the condition of NAFLD.